<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">TCM</journal-id><journal-title-group><journal-title>Traditional Chinese Medicine</journal-title></journal-title-group><issn pub-type="epub">2166-6067</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/TCM.2021.102027</article-id><article-id pub-id-type="publisher-id">TCM-40936</article-id><article-categories><subj-group subj-group-type="heading"><subject>TCM20210200000_86512383.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  乌梅丸方加减治疗帕金森病非运动性症状的疗效
  Effect of Modified Wumei Wan on Non-Motor Symptoms of Parkinson’s Disease
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>作文</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>时双</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孙</surname><given-names>景环</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>天寒</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>重庆市江津区中心医院，重庆医科大学附属江津中心医院神经内科，重庆</addr-line></aff><aff id="aff3"><addr-line>重庆市江津区中医院周天寒名老中医工作室，重庆</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>02</month><year>2021</year></pub-date><volume>10</volume><issue>02</issue><fpage>193</fpage><lpage>199</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：本研究旨在观察乌梅丸方加减对于帕金森病非运动性症状的疗效。方法：选择2018年6月至2020年5月神经内科诊断的PD患者56例，按入组先后顺序，采用随机区组法将患者1:1分为治疗组和对照组。入组后两组基础治疗的西药不变，治疗组给予乌梅丸方加减配伍的中药颗粒剂，对照组给予中药颗粒安慰剂，治疗4周后，观察两组的UPDRS评分、NMSQuest评分、PDSS评分及HAMD评分等。结果：两组患者基线资料无差异，治疗前两组UPDRS评分、NMSQuest评分、PDSS评分及HAMD评分无统计学差异，两组UPDRS评分、NMSQuest评分、PDSS评分及HAMD评分治疗前后的差值有统计学差异(P &lt; 0.01)。结论：乌梅丸方加减可以有效控制PD运动症状，对于非运动性症状也有较好的改善作用。 Objective: The purpose of this study was to observe the effect of modified Wumei Wan on non-motor symptoms of Parkinson’s disease. Method: A total of 56 patients with PD, who were diagnosed in the Department of Neurology from June 2018 to September 2020, were divided into study group and control group by 1:1 using randomized block design, according to the order of enrolled. After enrollment, patients in the two groups were treated with western medicine as before, the treatment group was given modified Wumei Wan herbal concentrate-granules, and the control group was given herbal concentrate-granules placebo. After 4 weeks of treatment, the UPDRS score, NMSQuest score, PDSS score and HAMD score of the two groups were observed. Results: There was no difference in baseline data between the two groups. There were no statistical differences in UPDRS score, NMSQuest score, PDSS score and HAMD score between the two groups before and after treatment, but there were statistical differences in differences of UPDRS score, NMSQuest score, PDSS score and HAMD score before and after treatment between the two groups (P &lt; 0.01). Conclusion: Modified Wumei Wan can effectively control PD motor symptoms and also has a good effect on non-motor symptoms. 
  
 
</p></abstract><kwd-group><kwd>乌梅丸，厥阴病，帕金森病，非运动症状, Wumei Wan</kwd><kwd> Jueyin Disease</kwd><kwd> Parkinson’s Disease</kwd><kwd> Non-Motor Symptoms</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：本研究旨在观察乌梅丸方加减对于帕金森病非运动性症状的疗效。方法：选择2018年6月至2020年5月神经内科诊断的PD患者56例，按入组先后顺序，采用随机区组法将患者1:1分为治疗组和对照组。入组后两组基础治疗的西药不变，治疗组给予乌梅丸方加减配伍的中药颗粒剂，对照组给予中药颗粒安慰剂，治疗4周后，观察两组的UPDRS评分、NMSQuest评分、PDSS评分及HAMD评分等。结果：两组患者基线资料无差异，治疗前两组UPDRS评分、NMSQuest评分、PDSS评分及HAMD评分无统计学差异，两组UPDRS评分、NMSQuest评分、PDSS评分及HAMD评分治疗前后的差值有统计学差异(P &lt; 0.01)。结论：乌梅丸方加减可以有效控制PD运动症状，对于非运动性症状也有较好的改善作用。</p></sec><sec id="s2"><title>关键词</title><p>乌梅丸，厥阴病，帕金森病，非运动症状</p></sec><sec id="s3"><title>Effect of Modified Wumei Wan on Non-Motor Symptoms of Parkinson’s Disease</title><p>Zuowen Zhang<sup>1*</sup>, Shishuang Li<sup>1</sup>, Jinghuan Sun<sup>2</sup>, Tianhan Zhou<sup>2</sup></p><p><sup>1</sup>Department of Neurology, Jiangjin Central Hospital of Chongqing, Jiangjin Central Hospital Affiliated to Chongqing Medical University, Chongqing</p><p><sup>2</sup>Zhou Tianhan famous TCM studio, Jiangjin TCM Hospital, Chongqing</p><p><img src="//html.hanspub.org/file/9-2270656x4_hanspub.png" /></p><p>Received: Feb. 4<sup>th</sup>, 2021; accepted: Mar. 8<sup>th</sup>, 2021; published: Mar. 15<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/9-2270656x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: The purpose of this study was to observe the effect of modified Wumei Wan on non-motor symptoms of Parkinson’s disease. Method: A total of 56 patients with PD, who were diagnosed in the Department of Neurology from June 2018 to September 2020, were divided into study group and control group by 1:1 using randomized block design, according to the order of enrolled. After enrollment, patients in the two groups were treated with western medicine as before, the treatment group was given modified Wumei Wan herbal concentrate-granules, and the control group was given herbal concentrate-granules placebo. After 4 weeks of treatment, the UPDRS score, NMSQuest score, PDSS score and HAMD score of the two groups were observed. Results: There was no difference in baseline data between the two groups. There were no statistical differences in UPDRS score, NMSQuest score, PDSS score and HAMD score between the two groups before and after treatment, but there were statistical differences in differences of UPDRS score, NMSQuest score, PDSS score and HAMD score before and after treatment between the two groups (P &lt; 0.01). Conclusion: Modified Wumei Wan can effectively control PD motor symptoms and also has a good effect on non-motor symptoms.</p><p>Keywords:Wumei Wan, Jueyin Disease, Parkinson’s Disease, Non-Motor Symptoms</p><disp-formula id="hanspub.40936-formula17"><graphic xlink:href="//html.hanspub.org/file/9-2270656x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/9-2270656x8_hanspub.png" /> <img src="//html.hanspub.org/file/9-2270656x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>帕金森病(Parkinson’s disease, PD)是老年人常见的神经系统变性疾病之一，国内一项流行病学调查结果显示：55岁以上的中国人中约有170多万PD患者，患病率达1%，与欧美国家接近 [<xref ref-type="bibr" rid="hanspub.40936-ref1">1</xref>]。除运动性症状之外，绝大多数患者在疾病的中晚期均会出现包括精神障碍、睡眠障碍、自主神经功能紊乱等在内的症候群，即非运动性症状(non-motor sympoms, NMS)，在疾病的发生发展过程中给患者带来较为严重的影响，加重运动障碍、缩短寿命、降低生活质量 [<xref ref-type="bibr" rid="hanspub.40936-ref2">2</xref>]。</p><p>PD非运动症状在中医理论中并无明确的病名及相应的分型，根据临床表现，常将它们分别归于“郁证”、“痴呆”、“不寐”、“自汗”、“便秘”等范畴，且在临证时通常将其作为辨证的重要依据。历代中医针对帕金森非运动症状的临床治疗资料较少，一方面与医生对于PD非运动症状认识不足有关；另一方面，传统的中医学辨证论治将这些非运动症状作为帕金森病辨证治疗时的辨证依据之一，从而掩盖了中药对非运动障碍症状的控制效果。我们前期的临床研究发现 [<xref ref-type="bibr" rid="hanspub.40936-ref3">3</xref>]，乌梅丸加味方联合多巴丝肼片能够有效控制PD患者运动性症状。在此基础上，本研究旨在通过设计一项随机、对照研究，评价乌梅丸加味方对于PD发病过程中对于非运动性症状的疗效。</p></sec><sec id="s6"><title>2. 对象与方法</title><p>1) 对象本研究的所有入选病例，均来自重庆市江津区中心医院及重庆市江津区中医院2018年6月至2020年5月神经内科门诊及住院治疗的PD患者56例。治疗组最小年龄52岁，最大年龄85岁；对照组最小年龄53岁，最大年龄80岁；治疗组病程最短8月，最长病程48月；对照组最短病程11月，最长病程42月。见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Characteristics of the Patients in two groups at Baselin</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >性别(男/女)</th><th align="center" valign="middle" >年龄(岁)</th><th align="center" valign="middle" >病程(月)</th></tr></thead><tr><td align="center" valign="middle" >治疗组</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >21/7</td><td align="center" valign="middle" >67.79 &#177; 9.37</td><td align="center" valign="middle" >26.04 &#177; 10.39</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >19/9</td><td align="center" valign="middle" >67.43 &#177; 8.70</td><td align="center" valign="middle" >26.43 &#177; 9.32</td></tr></tbody></table></table-wrap><p>表1. 两组患者基线资料对比</p><p>2) 诊断标准及纳入标准：</p><p>西医诊断标准：参考中华医学会神经病学分会帕金森病及运动障碍学组、中国医师协会神经内科医师分会帕金森病及运动障碍专业委员会《中国帕金森病的诊断标准(2016版)》以及国际运动障碍学会(MDS) 2015年推出的帕金森病临床诊断标准。帕金森病轻重程度采用Hoehn-Yahr分级法评定。</p><p>中医诊断标准：参照中华中医药学会在2008年颁布的《中医内科常见病诊疗指南》中“颤病”的诊断标准，并结合《中药新药临床研究指导原则》(2002)。</p><p>纳入标准：a) 符合中西医诊断标准，Hoehn-Yahr分级为2~4级者；b) 年龄在50~85岁者；c) 无认知障碍，自愿参加本临床试验并签署知情同意书者。</p><p>3) 排除标准：a) 帕金森综合征和帕金森叠加征患者；b) 严重脑卒中病史引起的肢体功能障碍者；c) 有严重高血压(血压 &gt; 180/120 mmHg)，控制不满意者；d) 有严重心、肝、脾、肺、肾、造血系统、骨关节疾病、重症感染者；e) 有严重精神症状或疾病者；f) 孕期及哺乳期妇女；g) 有滥用药物史或酗酒史者；h) 近3个月内参加其他临床试验者；i) 过敏体质及对试验药已知成分过敏者。</p><p>4) 剔除标准：a) 纳入对象不符合标准而误纳入者；b) 依从性差、未按本研究方案用药者；c) 资料不全无法统计者。</p><p>5) 脱落标准：a) 患者因突然某些严重疾病或并发症不宜继续试验；b) 患者出现严重不良事件而不宜继续试验；c) 患者因个人原因自行退出或未完成整个疗程而影响疗效或安全性判断。</p><p>6) 试验分组及用药方案</p><p>本研究方案通过重庆市江津区中心医院伦理委员会审查。按照入组顺序，采用随机数字表按区组设计随机分配至中药治疗组或对照组(中药安慰剂组)，1:1分配。两组中药均采用单味中药配方颗粒，服用方法为每天3次，每次150 ml开水冲服。治疗组方药：乌梅丸方加减(乌梅30 g，细辛5 g，干姜15 g，黄连10 g，当归30 g，制附片15 g，花椒10 g，桂枝15 g，党参10 g，黄柏10 g，鸡血藤30 g，白芍30 g，炙甘草10 g)，对照组取治疗组原方1/20的药量，余量用麦芽糊精、食用色素补充。其颜色、气味、外观、包装及服用方法等基本与治疗组相同。</p><p>给药方法：研究医生和受试者均设盲，研究医生给予受试者开具中药处方，药物管理人员管理信封并按受试者编号发药。治疗组、对照组在健康教育及西药基础治疗基础上分别予以中药治疗和中药安慰剂治疗，治疗疗程均为4周。治疗过程中药物及剂量按个体化原则继续入组前的用量，2组病例在试验观察期内不改变西药种类，原则上不再调整西药用量，如果西药增加或减少者，需做详细记录。</p><p>7) 观察指标</p><p>a) 帕金森病统一评分量表</p><p>帕金森病统一评分量表(Unified Parkinson’s Disease Rating Scale, UPDRS)是PD研究和临床工作室普遍应用的量表 [<xref ref-type="bibr" rid="hanspub.40936-ref4">4</xref>]，具有较高的信度、效度以及良好的可靠性和一致性，该量表包括4个方面，共42项：I) 精神、行为和情绪：包括智力情况，思维情况，抑郁和主动性4项，总分16分；II) 日常生活活动：包括言语，吞咽，唾液分泌，刀切食物和使用餐具，书写，穿衣，翻身和整理床单，个人卫生，跌跤，行走，行走中冻结，震颤，与帕金森病有关的感觉主诉共18项，总分52分；III) 运动检查：语言，面目表情，面部、唇部、下颌及四肢的静止性震颤，双上肢的手部动作性或姿势性震颤，双手指拍打实验，双手运动，双手轮替，颈部及四肢的强直，双下肢灵活性，姿势，姿势的稳定性，起立和躯体少动共11项，总分108分；IV) 治疗的并发症：异动症的持续时间、致残程度、疼痛程度及清晨肌张力不全，在“开”、“关”期的程度差异，病人有无睡眠障碍，有无食欲减退、恶心呕吐，有无症状性位置性障碍，共11项，总分23分。该量表的总分为199分。其分值越高，表示患者的病情越重。</p><p>b) 非运动症状筛查问卷(NMSQuest) [<xref ref-type="bibr" rid="hanspub.40936-ref5">5</xref>]</p><p>两组非运动症状(NMS)发生率评定参照NMSQuest制定标准，包括30个问题，答案分为“是”或“否”2个选项，“是”计1分，“否”不计分，分数越高，提示NMS程度越严重。</p><p>c) 帕金森病睡眠量表(PDSS) [<xref ref-type="bibr" rid="hanspub.40936-ref6">6</xref>]</p><p>两组睡眠状况评定参照PDSS制定标准，包括15项，每项按0~10分计分，得分越低，表明睡眠状况越差。</p><p>d) 汉密尔顿抑郁量表(HAMD) [<xref ref-type="bibr" rid="hanspub.40936-ref7">7</xref>]</p><p>两组抑郁情况评定参照HAMD制定标准，HAMD评分 ≥ 8分，提示存在抑郁情绪，分值越高，表明抑郁情况越严重。</p><p>e) 观察方法</p><p>在入组时对患者的姓名、性别、年龄、PD病程及基础疾病、PD服药情况等进行记录。两组患者的疗效指标于治疗前及治疗后4周分别进行2次评估，在评估前一天电话提醒患者回院复诊。每位受试者均在单独的房间里进行评估，评估过程可由患者及其家属共同参与，评估由笔者以检查和访谈形式完成。</p><p>8) 统计学处理</p><p>使用SPSS 22.0统计软件对所有数据进行分析与处理，并根据资料特点采用相应的统计方法。实验结果以 x &#175; &#177; s 来表示，其中计量资料需进行正态性检验，若符合正态分布，治疗前后的比较采用配对t检验，两样本均数的比较采用两个独立样本的t检验，不符合正态分布用非参数检验。计数资料采用卡方检验。检验水准P &lt; 0.05时差异有统计学意义。</p></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 一般资料比较</title><p>对比两组患者的性别、年龄、病程和合并疾病情况，结果显示两组性别无统计学差异；两组年龄无统计学差异；两组合并基础疾病无差异。一般资料均显示两组数据具有可比性。</p></sec><sec id="s7_2"><title>3.2. 两组UPDRS总分比较</title><p>治疗前，两组患者的UPDRS总分比较，差异无统计学意义(P &gt; 0.05)，两组数据具有可比性；治疗4周后，两组数据UPDRS总分较治疗前比较均下降；两组治疗前后UPDRS差值有显著性差异(P &lt; 0.01)。见表2。</p></sec><sec id="s7_3"><title>3.3. 两组HAMD评分比较</title><p>治疗前，两组患者HAMD评分比较，差异无统计学意义(P &gt; 0.05)，两组数据具有可比性；治疗4周后，两组数据组内比较，均较前下降；两组治疗前后HAMD评分差值差异有统计学意义(P &lt; 0.01)。见表3。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> The total scores of UPDRS before and 4 weeks after treatment and the difference of the total scores of UPDRS before and after treatment were compared between 2 groups ( x &#175; &#177; s </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >治疗前</th><th align="center" valign="middle" >治疗4周后</th><th align="center" valign="middle" >治疗前后差值</th></tr></thead><tr><td align="center" valign="middle" >治疗组</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >53.43 &#177; 17.96<sup>△</sup></td><td align="center" valign="middle" >47.89 &#177; 17.17</td><td align="center" valign="middle" >5.54&#177; 1.73<sup>▲</sup></td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >52.29 &#177; 13.66</td><td align="center" valign="middle" >51.00 &#177; 13.56</td><td align="center" valign="middle" >1.29 &#177; 0.98</td></tr></tbody></table></table-wrap><p>表2. 两组患者治疗前、治疗4周后UPDRS总分及治疗前后UPDRS总分差值比较( x &#175; &#177; s )</p><p>注：<sup>△</sup>两组治疗前UPDRS总分P &gt; 0.05；<sup>▲</sup>两组治疗前后UPDRS总分差值P &lt; 0.05。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> The scores of HAMD before and 4 weeks after treatment and the difference of the scores of HAMD before and after treatment were compared between 2 groups ( x &#175; &#177; s </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >治疗前</th><th align="center" valign="middle" >治疗4周后</th><th align="center" valign="middle" >治疗前后差值</th></tr></thead><tr><td align="center" valign="middle" >治疗组</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >20.00&#177;9.84<sup>△</sup></td><td align="center" valign="middle" >17.61&#177;8.70</td><td align="center" valign="middle" >2.39&#177;1.55<sup>▲</sup></td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >19.18&#177;8.54</td><td align="center" valign="middle" >18.14&#177;8.37</td><td align="center" valign="middle" >1.04&#177;0.74</td></tr></tbody></table></table-wrap><p>表3. 两组患者治疗前、治疗4周后HAMD评分及治疗前后HAMD评分差值比较( x &#175; &#177; s )</p><p>注：<sup>△</sup>两组治疗前HAMD评分P &gt; 0.05；<sup>▲</sup>两组治疗前后HAMD评分差值P &lt; 0.05。</p></sec><sec id="s7_4"><title>3.4. 两组NMS-Quest项数比较</title><p>治疗前，两组患者NMS-Quest项数比较，差异无统计学意义(P &gt; 0.05)，两组数据具有可比性；治疗4周后，两组数据组内比较，均较治疗前下降；两组治疗前后NMS-Quest项数差值差异有统计学意义(P &lt; 0.01)。见表4。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> The scores of NMS-Quest before and 4 weeks after treatment and the difference of the scores of NMS-Quest before and after treatment were compared between 2 groups ( x &#175; &#177; s </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >治疗前</th><th align="center" valign="middle" >治疗4周后</th><th align="center" valign="middle" >治疗前后差值</th></tr></thead><tr><td align="center" valign="middle" >治疗组</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >11.43 &#177; 3.84<sup>△</sup></td><td align="center" valign="middle" >9.18 &#177; 2.64</td><td align="center" valign="middle" >2.25 &#177; 1.53<sup>▲</sup></td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >11.64 &#177; 3.27</td><td align="center" valign="middle" >10.93 &#177; 3.29</td><td align="center" valign="middle" >0.71 &#177; 0.60</td></tr></tbody></table></table-wrap><p>表4. 两组患者治疗前、治疗4周后NMS-Quest及治疗前后NMS-Quest差值比较( x &#175; &#177; s )</p><p>注：<sup>△</sup>两组治疗前NMS-Quest项数P &gt; 0.05；<sup>▲</sup>两组治疗前后NMS-Quest项数差值P &lt; 0.05。</p></sec><sec id="s7_5"><title>3.5. 两组PDSS评分比较</title><p>治疗前，两组患者PDSS评分比较，差异无统计学意义(P &gt; 0.05)，两组数据具有可比性；治疗4周后，两组数据组内比较，均较治疗前升高；两组治疗后前PDSS评分差值差异有统计学意义(P &lt; 0.01)。见表5。</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> The scores of PDSS before and 4 weeks after treatment and the difference of the scores of PDSS before and after treatment were compared between 2 groups ( x &#175; &#177; s </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >治疗前</th><th align="center" valign="middle" >治疗4周后</th><th align="center" valign="middle" >治疗前后差值</th></tr></thead><tr><td align="center" valign="middle" >治疗组</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >62.96 &#177; 25.79<sup>△</sup></td><td align="center" valign="middle" >89.68 &#177; 21.97</td><td align="center" valign="middle" >26.71 &#177; 11.56<sup>▲</sup></td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >63.21 &#177; 28.02</td><td align="center" valign="middle" >73.36 &#177; 29.47</td><td align="center" valign="middle" >10.14 &#177; 5.05</td></tr></tbody></table></table-wrap><p>表5. 两组患者治疗前、治疗4周后PDSS评分及治疗后前PDSS评分差值比较( x &#175; &#177; s )</p><p>注：<sup>△</sup>两组治疗前PDSS评分P &gt; 0.05；<sup>▲</sup>两组治疗前后PDSS评分差值P &lt; 0.05。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>2003年，Braak等 [<xref ref-type="bibr" rid="hanspub.40936-ref8">8</xref>] 创立假说，对帕金森病病理演变过程与运动或非运动症状之间的关系作出了较为合理的解释，从而为更好地识别帕金森病非运动症状提供了理论依据和可能。根据Braak假说，在运动症状(累及中脑黑质)出现前期，脑组织α-突触共核蛋白主要累及嗅球、迷走神经背侧运动核、延髓及脑桥被盖等，表现为嗅觉障碍、吞咽困难、抑郁症状、睡眠障碍及疼痛；而在运动症状出现后期则累及边缘系统和新皮质，这在一定程度上解释了帕金森病中晚期患者出现幻视等精神和痴呆症状的原因。</p><p>六经辨证中，疾病进展至厥阴病阶段，处于阴尽阳生、阴中有阳的状态。此阶段有“阴阳气不相顺接”的“厥证”，也有“上热下寒”之寒热错杂。帕金森病的运动减少及震颤这两大主要运动症状群均可用厥阴病的一阳初生、阳气不足，肝之疏泄太过、风气内动来解释。我们前期提出了“从厥阴病论治帕金森病”的学术观点 [<xref ref-type="bibr" rid="hanspub.40936-ref9">9</xref>]，前期的临床研究发现 [<xref ref-type="bibr" rid="hanspub.40936-ref3">3</xref>]，乌梅丸加味方联合多巴丝肼片能够有效控制PD患者运动性症状，同时也观察到对于疼痛、疲乏、排便障碍、多汗等非运动性症状也有疗效。对于帕金森病非运动性症状，我们认为阳虚贯穿其整个病机过程。比如睡眠障碍，《石山医案•阳虚》 [<xref ref-type="bibr" rid="hanspub.40936-ref10">10</xref>] 中论曰：“今阳既虚，则阳之精气不能养神，而心藏神，神失所养，则飘荡飞扬而多梦矣……魂亦不藏，故梦寐欠安。”抑郁障碍，《素问•脉解篇》：“所谓欲独闭户牖而处者，阴阳相薄也，阳尽而阴盛，故欲独闭户牖而居。”《景岳全书•中兴论》曰：“阳主神也”。而在认知功能方面，《素问•四时刺逆从论》云：“阳气竭绝，令人善忘。”故阳气虚与非运动症状密切相关。乌梅丸中，蜀椒、干姜、人参乃大建中之主药，大建中脏之阳；附子、干姜，乃四逆汤之主药，功能回阳救逆；当归、桂枝、细辛，含当归四逆汤主药；以上可补阳气之虚，以扶一阳之馁弱。肝与心包二脏，皆内有相火，内郁而化热，故以芩连参姜附，寓泻心之意，调其寒热复中州斡旋之功，升降之职；共襄扶阳调寒热，使阴阳臻于和平 [<xref ref-type="bibr" rid="hanspub.40936-ref11">11</xref>]。</p><p>本研究显示，乌梅丸方加减可显著改善患者UPDRS评分，明显改善帕金森病患者的运动症状。而对于非运动性症状，尤其睡眠障碍、抑郁等，乌梅丸方加减同样有显著的改善作用。非运动性症状的问卷调查显示，乌梅丸方加减对于帕金森病患者在便秘、流涎、情绪以及疼痛方面也有明显效果。然而本研究限于样本量小，研究结果可能存在偏倚，而且难以精确分析该疗法对UPDRS量表中精神、运动、并发症等不同方面的影响是否存在差异。下一步可扩大样本量对各分量进行针对性研究，以及进一步探索该疗法对于认知功能的影响。</p></sec><sec id="s9"><title>基金项目</title><p>重庆市科卫联合中医药科技重点项目(ZY201801011)，国家中医药管理局第六批全国老中医药专家学术经验继承项目(国中医药人教发〔2017〕29号)。</p></sec><sec id="s10"><title>文章引用</title><p>张作文,李时双,孙景环,周天寒. 乌梅丸方加减治疗帕金森病非运动性症状的疗效Effect of Modified Wumei Wan on Non-Motor Symptoms of Parkinson’s Disease[J]. 中医学, 2021, 10(02): 193-199. https://doi.org/10.12677/TCM.2021.102027</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40936-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Z.X., Roman, G.C., Hong, Z., et al. (2005) Parkinson’s Disease in China: Prevalence in Beijing, Xian, and Shanghai. Lancet, 365, 595-597. &lt;br&gt;https://doi.org/10.1016/S0140-6736(05)70801-1</mixed-citation></ref><ref id="hanspub.40936-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Chaudhuri, K.R., Healy, D.G., Schapira, A.H. and National Institute for Clinical Excellence (2006) Non-Motor Symptoms of Parkinson’s Disease: Diagnosis and Management. The Lancet Neurology, 5, 235-245.  
&lt;br&gt;https://doi.org/10.1016/S1474-4422(06)70373-8</mixed-citation></ref><ref id="hanspub.40936-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">张作文, 车福友, 撒俊鹏, 等. 从厥阴病论治帕金森病26例临床分析[J]. 中国中医药信息杂志, 2012, 19(7): 62-63.</mixed-citation></ref><ref id="hanspub.40936-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Rabey, J.M., Bass, H., Bonuccelli, U., et al. (1997) Evaluation of the Short Parkinson’s Evaluation Scale: A New Friendly Scale for the Evaluation of Parkinson’s Disease in Clinical Drug Trials. Clinical Neuropharmacology, 20, 322-337. &lt;br&gt;https://doi.org/10.1097/00002826-199708000-00004</mixed-citation></ref><ref id="hanspub.40936-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Chaudhuri, K.R., Martinez-Martin, P., Schapira, A.H., et al. (2006) International Multicenter Pilot Study of the First Comprehensive Self-Completed Nonmotor Symptoms Questionnaire for Parkinson’s Disease: The NMSQuest Study. Movement Disorders, 21, 916-923. &lt;br&gt;https://doi.org/10.1002/mds.20844</mixed-citation></ref><ref id="hanspub.40936-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Chaudhuri, K.R., Pal, S., DiMarco, A., et al. (2002) The Parkinson’s Disease Sleep Scale: A New Instrument for Assessing Sleep and Nocturnal Disability in Parkinson’s Disease. Journal of Neurology, Neurosurgery and Psychiatry, 73, 629-635. &lt;br&gt;https://doi.org/10.1136/jnnp.73.6.629</mixed-citation></ref><ref id="hanspub.40936-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Hamilton, M. (1960) A Rating Scale for Depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 56-62.  
&lt;br&gt;https://doi.org/10.1136/jnnp.23.1.56</mixed-citation></ref><ref id="hanspub.40936-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Braak, H., Del Tredici, K., Rüb, U., et al. (2003) Staging of Brain Pathology Related to Sporadic Parkinson’s Disease. Neurobiology of Aging, 24, 197-211. &lt;br&gt;https://doi.org/10.1016/S0197-4580(02)00065-9</mixed-citation></ref><ref id="hanspub.40936-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">张作文, 车福友, 胡代英. 从厥阴病论治帕金森病[J]. 国际中医中药杂志, 2012, 34(6): 542-543.</mixed-citation></ref><ref id="hanspub.40936-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">汪石山. 汪石山医学全书[M]. 北京: 中国中医药出版社, 1999: 96.</mixed-citation></ref><ref id="hanspub.40936-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">李士懋. 论乌梅丸的临床应用[C]//中华中医药学会. 国际(中日韩)经方学术会议第二届全国经方论坛暨经方应用高级研修班论文集, 北京: 中华中医药学会, 2011: 289.  
https://navi.cnki.net/KNavi/DPaperDetail?pcode=CIPD&amp;lwjcode=ZHZY201105004&amp;hycode=013963</mixed-citation></ref></ref-list></back></article>